Celerus Diagnostics
Founded Year
2004Stage
Series C - II | AliveTotal Raised
$15MLast Raised
$10M | 12 yrs agoAbout Celerus Diagnostics
Celerus Diagnostics is aiming to enhance the diagnostic capabilities of the pathology laboratory. Celerus' Rapid IHC technology aims to provide the capability to decentralize testing, and move results closer to the patient for real time decision making.
Loading...
Loading...
Celerus Diagnostics Patents
Celerus Diagnostics has filed 4 patents.

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
4/21/2006 | 5/15/2012 | Staining, Outlines of countries, Microscopy, Staining dyes, Electromechanical engineering | Grant |
Application Date | 4/21/2006 |
---|---|
Grant Date | 5/15/2012 |
Title | |
Related Topics | Staining, Outlines of countries, Microscopy, Staining dyes, Electromechanical engineering |
Status | Grant |
Celerus Diagnostics Frequently Asked Questions (FAQ)
When was Celerus Diagnostics founded?
Celerus Diagnostics was founded in 2004.
Where is Celerus Diagnostics's headquarters?
Celerus Diagnostics's headquarters is located at 1005 Mark Ave, Carpinteria.
What is Celerus Diagnostics's latest funding round?
Celerus Diagnostics's latest funding round is Series C - II.
How much did Celerus Diagnostics raise?
Celerus Diagnostics raised a total of $15M.
Who are the investors of Celerus Diagnostics?
Investors of Celerus Diagnostics include Hamilton BioVentures and Persistence Partners.
Who are Celerus Diagnostics's competitors?
Competitors of Celerus Diagnostics include Affidea, Armune Bioscience, Magellan Biosciences, Crescendo Bioscience, Alverix and 7 more.
Loading...
Compare Celerus Diagnostics to Competitors

Mediracer Specialises In Medical Technology. The company's Core Business Is The Development, Manufacture And Global Sale Of Point Of Care (poc) Diagnostic Testing Equipment For Diseases Of The Peripheral Nervous System.
Micronics, Inc. is a developer of near patient in vitro diagnostic products for disease diagnosis, prognosis and treatment monitoring. The Company employs a core patent estate in microfluidics -- the ability to miniaturize complex tests onto credit card size disposable devices. Per the company, tests that today take hours to days in a central laboratory environment are processed on a Micronics disposable device in seconds to minutes.
NIR Diagnostics is developing a diagnostic device to quantitatively assess the progress of the wound healing process. Per the company, the device has the potential to be a more accurate, more rapid, and less expensive method of wound assessment compared to those currently on the market.
Kjaya is a company that received a SBIR Phase I grant for a project entitled: Semi-Autonomous Adaptive Neural and Genetic Segmentation of Medical Images. Their Phase I project will implement a physician-assisted, real-time adaptive system for the segmentation of anatomical structures in 3D medical image data. Medical image segmentation seeks to change the representation of an anatomical structure, making it more easily analyzed. Because of the extreme variability of these structures in biological systems, current idiosyncratic manual methods currently in use are tedious, time consuming, and error prone. Image segmentation cannot in general be programmatically solved. The proposed system is a Neural Network (NN) based adaptation of the individual data using parallel Graphics Processing Units (GPUs) and coupled with a Genetic Algorithm (GA) based adaptation across GPU cores. The system will build a diagnostically useful segmentation of the anatomical feature within seconds from an area of interest outlined by a physician using a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Fast growth in medical imaging overwhelms available diagnosticians. An intuitive and inexpensive system to quickly and accurately deliver diagnostic relevant segmentation of medical images offers tremendous commercial value. Currently, each scan requires approximately 50 minutes of manual preparation. The diagnosis and treatment of an estimated 20 percent of diseases benefit from medical imaging. Newer scanning technologies have increased in resolution, but such techniques have not made segmenting easier or faster. The proposed method will enable more diagnostics to be done with the quality controlled directly by physicians.
Beacon Develops immunodiagnostic kits for environmental & food/feed testing markets
Knoesis seeks to develop bio-analytical hardware and reagents enabling cost-effective clinical diagnostics. The vision of the company is to allow everyone affordable access to rapid and specific diagnostic healthcare knowledge. Knoesis' first application is an immunosensor for the detection of latent tuberculosis infection.
Loading...